CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region

Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as cognitive-enhancing effect. We previously showed that nefiracetam potentiates NMDA-induced currents in cultured rat cortical neurons. To address questions whether nefiracetam affects NMDA receptor-...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neurochemistry 2008-08, Vol.106 (3), p.1092-1103
Hauptverfasser: Moriguchi, Shigeki, Shioda, Norifumi, Han, Feng, Narahashi, Toshio, Fukunaga, Kohji
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1103
container_issue 3
container_start_page 1092
container_title Journal of neurochemistry
container_volume 106
creator Moriguchi, Shigeki
Shioda, Norifumi
Han, Feng
Narahashi, Toshio
Fukunaga, Kohji
description Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as cognitive-enhancing effect. We previously showed that nefiracetam potentiates NMDA-induced currents in cultured rat cortical neurons. To address questions whether nefiracetam affects NMDA receptor-dependent synaptic plasticity in the hippocampus, we assessed effects of nefiracetam on NMDA receptor-dependent long-term potentiation (LTP) by electrophysiology and LTP-induced phosphorylation of synaptic proteins by immunoblotting analysis. Nefiracetam treatment at 1-1000 nM increased the slope of fEPSPs in a dose-dependent manner. The enhancement was associated with increased phosphorylation of α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor through activation of calcium/calmodulin-dependent protein kinase II (CaMKII) without affecting synapsin I phosphorylation. In addition, nefiracetam treatment increased PKCα activity in a bell-shaped dose-response curve which peaked at 10 nM, thereby increasing phosphorylation of myristoylated alanine-rich protein kinase C substrate and NMDA receptor. Nefiracetam treatment did not affect protein kinase A activity. Consistent with the bell-shaped PKCα activation, nefiracetam treatment enhanced LTP in the rat hippocampal CA1 region with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with CaMKII and PKCα activation with concomitant increases in phosphorylation of their endogenous substrates except for synapsin I. These results suggest that nefiracetam potentiates AMPA receptor-mediated fEPSPs through CaMKII activation and enhances NMDA receptor-dependent LTP through potentiation of the post-synaptic CaMKII and protein kinase C activities. Together with potentiation of nicotinic acetylcholine receptor function, nefiracetam-enhanced AMPA and NMDA receptor functions likely contribute to improvement of cognitive function.
doi_str_mv 10.1111/j.1471-4159.2008.05440.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69403109</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69403109</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5950-ee949e2e1369e658addd3a6c5215cf7800674941b8fd46cac07d24bfff6f702d3</originalsourceid><addsrcrecordid>eNqNkd-O1CAUhxujccfVV1BionetBwq0vfBi0_hnzKoXuteEoYcZxpZ2oaM7D-E7y-yMa-KNcgOB73fg8GUZoVDQNF5tC8ormnMqmoIB1AUIzqG4uZct7g7uZwsAxvISODvLHsW4BaCSS_owO6M154KW1SL72eqP5JvzOiJZLon2HZnCOKPzv3dbos3svuvZjT6SATunZyToN9obHNDPZLSkH_06nzEMZEphP7tbnKz2xKN1QRuc9UBS0XmDJOiZbNw0jUYPk-5Je0FJwHUKPM4eWN1HfHKaz7Ort2--tu_zy8_vlu3FZW5EIyBHbHiDDGkpG5Si1l3XlVoawagwtqoBZMUbTle17bg02kDVMb6y1kpbAevK8-zlsW7q9XqHcVaDiwb7Xnscd1HJhkNJofknyKCuJKM0gc__ArfjLvjURGKkSJ8teILqI2TCGGNAq6bgBh32ioI6iFVbdfCnDv7UQay6FatuUvTpqf5ulRz8CZ5MJuDFCdDR6N6GpMfFO46BYKJsysS9PnI_XI_7_36A-vCpPaxS_tkxb_Wo9DqkO66-MKAlQEOFSH_2C36ax8Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>206551354</pqid></control><display><type>article</type><title>CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>IngentaConnect Free/Open Access Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Moriguchi, Shigeki ; Shioda, Norifumi ; Han, Feng ; Narahashi, Toshio ; Fukunaga, Kohji</creator><creatorcontrib>Moriguchi, Shigeki ; Shioda, Norifumi ; Han, Feng ; Narahashi, Toshio ; Fukunaga, Kohji</creatorcontrib><description>Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as cognitive-enhancing effect. We previously showed that nefiracetam potentiates NMDA-induced currents in cultured rat cortical neurons. To address questions whether nefiracetam affects NMDA receptor-dependent synaptic plasticity in the hippocampus, we assessed effects of nefiracetam on NMDA receptor-dependent long-term potentiation (LTP) by electrophysiology and LTP-induced phosphorylation of synaptic proteins by immunoblotting analysis. Nefiracetam treatment at 1-1000 nM increased the slope of fEPSPs in a dose-dependent manner. The enhancement was associated with increased phosphorylation of α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor through activation of calcium/calmodulin-dependent protein kinase II (CaMKII) without affecting synapsin I phosphorylation. In addition, nefiracetam treatment increased PKCα activity in a bell-shaped dose-response curve which peaked at 10 nM, thereby increasing phosphorylation of myristoylated alanine-rich protein kinase C substrate and NMDA receptor. Nefiracetam treatment did not affect protein kinase A activity. Consistent with the bell-shaped PKCα activation, nefiracetam treatment enhanced LTP in the rat hippocampal CA1 region with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with CaMKII and PKCα activation with concomitant increases in phosphorylation of their endogenous substrates except for synapsin I. These results suggest that nefiracetam potentiates AMPA receptor-mediated fEPSPs through CaMKII activation and enhances NMDA receptor-dependent LTP through potentiation of the post-synaptic CaMKII and protein kinase C activities. Together with potentiation of nicotinic acetylcholine receptor function, nefiracetam-enhanced AMPA and NMDA receptor functions likely contribute to improvement of cognitive function.</description><identifier>ISSN: 0022-3042</identifier><identifier>EISSN: 1471-4159</identifier><identifier>DOI: 10.1111/j.1471-4159.2008.05440.x</identifier><identifier>PMID: 18445137</identifier><identifier>CODEN: JONRA9</identifier><language>eng</language><publisher>Oxford, UK: Oxford, UK : Blackwell Publishing Ltd</publisher><subject>Adult and adolescent clinical studies ; Alzheimer disease ; Alzheimer’s disease ; Animals ; Biochemistry ; Biological and medical sciences ; Calcium-Calmodulin-Dependent Protein Kinase Type 2 - metabolism ; calcium/calmodulin-dependent protein kinase II ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Dose-Response Relationship, Drug ; Enzyme Activation - drug effects ; Enzyme Activation - physiology ; Hippocampus - drug effects ; Hippocampus - enzymology ; long-term potentiation ; Long-Term Potentiation - drug effects ; Long-Term Potentiation - physiology ; Male ; Medical sciences ; N-methyl- d-aspartate acid ; nefiracetam ; Neurology ; Neurotransmitters ; Organic mental disorders. Neuropsychology ; Pharmacology ; protein kinase C ; Protein Kinase C - metabolism ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Pyrrolidinones - pharmacology ; Rats ; Rats, Wistar ; Rodents</subject><ispartof>Journal of neurochemistry, 2008-08, Vol.106 (3), p.1092-1103</ispartof><rights>2008 The Authors. Journal Compilation © 2008 International Society for Neurochemistry</rights><rights>2008 INIST-CNRS</rights><rights>Journal compilation © 2008 International Society for Neurochemistry</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5950-ee949e2e1369e658addd3a6c5215cf7800674941b8fd46cac07d24bfff6f702d3</citedby><cites>FETCH-LOGICAL-c5950-ee949e2e1369e658addd3a6c5215cf7800674941b8fd46cac07d24bfff6f702d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1471-4159.2008.05440.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1471-4159.2008.05440.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,1430,27911,27912,45561,45562,46396,46820</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20525393$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18445137$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moriguchi, Shigeki</creatorcontrib><creatorcontrib>Shioda, Norifumi</creatorcontrib><creatorcontrib>Han, Feng</creatorcontrib><creatorcontrib>Narahashi, Toshio</creatorcontrib><creatorcontrib>Fukunaga, Kohji</creatorcontrib><title>CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region</title><title>Journal of neurochemistry</title><addtitle>J Neurochem</addtitle><description>Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as cognitive-enhancing effect. We previously showed that nefiracetam potentiates NMDA-induced currents in cultured rat cortical neurons. To address questions whether nefiracetam affects NMDA receptor-dependent synaptic plasticity in the hippocampus, we assessed effects of nefiracetam on NMDA receptor-dependent long-term potentiation (LTP) by electrophysiology and LTP-induced phosphorylation of synaptic proteins by immunoblotting analysis. Nefiracetam treatment at 1-1000 nM increased the slope of fEPSPs in a dose-dependent manner. The enhancement was associated with increased phosphorylation of α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor through activation of calcium/calmodulin-dependent protein kinase II (CaMKII) without affecting synapsin I phosphorylation. In addition, nefiracetam treatment increased PKCα activity in a bell-shaped dose-response curve which peaked at 10 nM, thereby increasing phosphorylation of myristoylated alanine-rich protein kinase C substrate and NMDA receptor. Nefiracetam treatment did not affect protein kinase A activity. Consistent with the bell-shaped PKCα activation, nefiracetam treatment enhanced LTP in the rat hippocampal CA1 region with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with CaMKII and PKCα activation with concomitant increases in phosphorylation of their endogenous substrates except for synapsin I. These results suggest that nefiracetam potentiates AMPA receptor-mediated fEPSPs through CaMKII activation and enhances NMDA receptor-dependent LTP through potentiation of the post-synaptic CaMKII and protein kinase C activities. Together with potentiation of nicotinic acetylcholine receptor function, nefiracetam-enhanced AMPA and NMDA receptor functions likely contribute to improvement of cognitive function.</description><subject>Adult and adolescent clinical studies</subject><subject>Alzheimer disease</subject><subject>Alzheimer’s disease</subject><subject>Animals</subject><subject>Biochemistry</subject><subject>Biological and medical sciences</subject><subject>Calcium-Calmodulin-Dependent Protein Kinase Type 2 - metabolism</subject><subject>calcium/calmodulin-dependent protein kinase II</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Dose-Response Relationship, Drug</subject><subject>Enzyme Activation - drug effects</subject><subject>Enzyme Activation - physiology</subject><subject>Hippocampus - drug effects</subject><subject>Hippocampus - enzymology</subject><subject>long-term potentiation</subject><subject>Long-Term Potentiation - drug effects</subject><subject>Long-Term Potentiation - physiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>N-methyl- d-aspartate acid</subject><subject>nefiracetam</subject><subject>Neurology</subject><subject>Neurotransmitters</subject><subject>Organic mental disorders. Neuropsychology</subject><subject>Pharmacology</subject><subject>protein kinase C</subject><subject>Protein Kinase C - metabolism</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Pyrrolidinones - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Rodents</subject><issn>0022-3042</issn><issn>1471-4159</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkd-O1CAUhxujccfVV1BionetBwq0vfBi0_hnzKoXuteEoYcZxpZ2oaM7D-E7y-yMa-KNcgOB73fg8GUZoVDQNF5tC8ormnMqmoIB1AUIzqG4uZct7g7uZwsAxvISODvLHsW4BaCSS_owO6M154KW1SL72eqP5JvzOiJZLon2HZnCOKPzv3dbos3svuvZjT6SATunZyToN9obHNDPZLSkH_06nzEMZEphP7tbnKz2xKN1QRuc9UBS0XmDJOiZbNw0jUYPk-5Je0FJwHUKPM4eWN1HfHKaz7Ort2--tu_zy8_vlu3FZW5EIyBHbHiDDGkpG5Si1l3XlVoawagwtqoBZMUbTle17bg02kDVMb6y1kpbAevK8-zlsW7q9XqHcVaDiwb7Xnscd1HJhkNJofknyKCuJKM0gc__ArfjLvjURGKkSJ8teILqI2TCGGNAq6bgBh32ioI6iFVbdfCnDv7UQay6FatuUvTpqf5ulRz8CZ5MJuDFCdDR6N6GpMfFO46BYKJsysS9PnI_XI_7_36A-vCpPaxS_tkxb_Wo9DqkO66-MKAlQEOFSH_2C36ax8Q</recordid><startdate>200808</startdate><enddate>200808</enddate><creator>Moriguchi, Shigeki</creator><creator>Shioda, Norifumi</creator><creator>Han, Feng</creator><creator>Narahashi, Toshio</creator><creator>Fukunaga, Kohji</creator><general>Oxford, UK : Blackwell Publishing Ltd</general><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200808</creationdate><title>CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region</title><author>Moriguchi, Shigeki ; Shioda, Norifumi ; Han, Feng ; Narahashi, Toshio ; Fukunaga, Kohji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5950-ee949e2e1369e658addd3a6c5215cf7800674941b8fd46cac07d24bfff6f702d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Alzheimer disease</topic><topic>Alzheimer’s disease</topic><topic>Animals</topic><topic>Biochemistry</topic><topic>Biological and medical sciences</topic><topic>Calcium-Calmodulin-Dependent Protein Kinase Type 2 - metabolism</topic><topic>calcium/calmodulin-dependent protein kinase II</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Dose-Response Relationship, Drug</topic><topic>Enzyme Activation - drug effects</topic><topic>Enzyme Activation - physiology</topic><topic>Hippocampus - drug effects</topic><topic>Hippocampus - enzymology</topic><topic>long-term potentiation</topic><topic>Long-Term Potentiation - drug effects</topic><topic>Long-Term Potentiation - physiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>N-methyl- d-aspartate acid</topic><topic>nefiracetam</topic><topic>Neurology</topic><topic>Neurotransmitters</topic><topic>Organic mental disorders. Neuropsychology</topic><topic>Pharmacology</topic><topic>protein kinase C</topic><topic>Protein Kinase C - metabolism</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Pyrrolidinones - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Rodents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moriguchi, Shigeki</creatorcontrib><creatorcontrib>Shioda, Norifumi</creatorcontrib><creatorcontrib>Han, Feng</creatorcontrib><creatorcontrib>Narahashi, Toshio</creatorcontrib><creatorcontrib>Fukunaga, Kohji</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moriguchi, Shigeki</au><au>Shioda, Norifumi</au><au>Han, Feng</au><au>Narahashi, Toshio</au><au>Fukunaga, Kohji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region</atitle><jtitle>Journal of neurochemistry</jtitle><addtitle>J Neurochem</addtitle><date>2008-08</date><risdate>2008</risdate><volume>106</volume><issue>3</issue><spage>1092</spage><epage>1103</epage><pages>1092-1103</pages><issn>0022-3042</issn><eissn>1471-4159</eissn><coden>JONRA9</coden><abstract>Nefiracetam is a pyrrolidine-related nootropic drug exhibiting various pharmacological actions such as cognitive-enhancing effect. We previously showed that nefiracetam potentiates NMDA-induced currents in cultured rat cortical neurons. To address questions whether nefiracetam affects NMDA receptor-dependent synaptic plasticity in the hippocampus, we assessed effects of nefiracetam on NMDA receptor-dependent long-term potentiation (LTP) by electrophysiology and LTP-induced phosphorylation of synaptic proteins by immunoblotting analysis. Nefiracetam treatment at 1-1000 nM increased the slope of fEPSPs in a dose-dependent manner. The enhancement was associated with increased phosphorylation of α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptor through activation of calcium/calmodulin-dependent protein kinase II (CaMKII) without affecting synapsin I phosphorylation. In addition, nefiracetam treatment increased PKCα activity in a bell-shaped dose-response curve which peaked at 10 nM, thereby increasing phosphorylation of myristoylated alanine-rich protein kinase C substrate and NMDA receptor. Nefiracetam treatment did not affect protein kinase A activity. Consistent with the bell-shaped PKCα activation, nefiracetam treatment enhanced LTP in the rat hippocampal CA1 region with the same bell-shaped dose-response curve. Furthermore, nefiracetam-induced LTP enhancement was closely associated with CaMKII and PKCα activation with concomitant increases in phosphorylation of their endogenous substrates except for synapsin I. These results suggest that nefiracetam potentiates AMPA receptor-mediated fEPSPs through CaMKII activation and enhances NMDA receptor-dependent LTP through potentiation of the post-synaptic CaMKII and protein kinase C activities. Together with potentiation of nicotinic acetylcholine receptor function, nefiracetam-enhanced AMPA and NMDA receptor functions likely contribute to improvement of cognitive function.</abstract><cop>Oxford, UK</cop><pub>Oxford, UK : Blackwell Publishing Ltd</pub><pmid>18445137</pmid><doi>10.1111/j.1471-4159.2008.05440.x</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3042
ispartof Journal of neurochemistry, 2008-08, Vol.106 (3), p.1092-1103
issn 0022-3042
1471-4159
language eng
recordid cdi_proquest_miscellaneous_69403109
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; IngentaConnect Free/Open Access Journals; Free Full-Text Journals in Chemistry
subjects Adult and adolescent clinical studies
Alzheimer disease
Alzheimer’s disease
Animals
Biochemistry
Biological and medical sciences
Calcium-Calmodulin-Dependent Protein Kinase Type 2 - metabolism
calcium/calmodulin-dependent protein kinase II
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Dose-Response Relationship, Drug
Enzyme Activation - drug effects
Enzyme Activation - physiology
Hippocampus - drug effects
Hippocampus - enzymology
long-term potentiation
Long-Term Potentiation - drug effects
Long-Term Potentiation - physiology
Male
Medical sciences
N-methyl- d-aspartate acid
nefiracetam
Neurology
Neurotransmitters
Organic mental disorders. Neuropsychology
Pharmacology
protein kinase C
Protein Kinase C - metabolism
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Pyrrolidinones - pharmacology
Rats
Rats, Wistar
Rodents
title CaM kinase II and protein kinase C activations mediate enhancement of long-term potentiation by nefiracetam in the rat hippocampal CA1 region
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T17%3A16%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CaM%20kinase%20II%20and%20protein%20kinase%20C%20activations%20mediate%20enhancement%20of%20long-term%20potentiation%20by%20nefiracetam%20in%20the%20rat%20hippocampal%20CA1%20region&rft.jtitle=Journal%20of%20neurochemistry&rft.au=Moriguchi,%20Shigeki&rft.date=2008-08&rft.volume=106&rft.issue=3&rft.spage=1092&rft.epage=1103&rft.pages=1092-1103&rft.issn=0022-3042&rft.eissn=1471-4159&rft.coden=JONRA9&rft_id=info:doi/10.1111/j.1471-4159.2008.05440.x&rft_dat=%3Cproquest_cross%3E69403109%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=206551354&rft_id=info:pmid/18445137&rfr_iscdi=true